Sure! Here’s the translation into American English:
—
The biotechnology company Servatrix Biomed, originating from the Autonomous University of Madrid, has launched a significant capital expansion campaign on the specialized biotechnology investment platform, Capital Cell, which is regulated by the National Securities Market Commission (CNMV). Since its launch on April 22, the company has managed to raise over 80% of its initial goal, exceeding 450,000 euros and attracting more than 90 new investors in record time.
This strong interest in the company suggests that Servatrix Biomed is establishing itself as one of the most promising opportunities in the Spanish biotechnology sector. Aiming to reach 550,000 euros, the funds raised will be allocated to accelerate the development of an innovative therapy aimed at treating fatty liver, a condition that affects more than 25% of the global population and currently lacks effective treatments.
Servatrix Biomed is led by Professor Antonio Cuadrado from the Department of Biochemistry at the Faculty of Medicine of the Autonomous University of Madrid. The company has developed a patented technology that focuses on oxidative stress mechanisms and cellular inflammation. Preclinical results have shown a significant reduction in liver inflammation and an improvement in metabolic profiles, which could halt the progression of the disease to more severe forms, such as fibrosis or cirrhosis.
The scientific validation of its proposal, along with robust industrial property and the potential of a market projected to reach $31 billion in the next decade, puts Servatrix in an enviable position. The recent FDA approval of a first treatment underscores the urgency and prospects in this therapeutic area.
In addition to its successful funding campaign, Servatrix Biomed has been recognized in the 9th edition of the HealthStart madri+d program, providing it with additional funding. This recognition validates the quality of its biomedical innovation proposal and its capacity to transform the treatment of liver diseases.
The company also stands out for the attractive terms it offers to its investors; it holds the innovative company seal from the Ministry of Science and Innovation, allowing for tax deductions of up to 50% on personal income tax for investments, all thanks to the Startup Law.
With a unique technology, a top-tier scientific team, and a global medical need, Servatrix Biomed is expected to be an exceptional investment. The enthusiasm generated in the first days of its campaign supports this vision.
The capital expansion campaign of Servatrix Biomed is still active and will remain open for the next 30 days. Private and individual investors have the opportunity to participate easily, securely, and regulated through the Capital Cell platform, with a minimum investment set at 1,000 euros.
Source: MiMub in Spanish
